| abstract |
The present application relates to epitope-targeted SIV and HIV vaccines. The invention provides novel envelope glycoproteins which may be utilized as HIV-l vaccine immunogens, antigens for crystallization, and for identification of broadly neutralizing antibodies, The invention encompasses preparation and purification of immunogenic compositions which are formulated into vaccines of the present invention. |